Peter Attia MD310 - The relationship between testosterone and prostate cancer, TRT, and more
At a glance
WHAT IT’S REALLY ABOUT
Ted Schaeffer on Testosterone, Androgen Receptors, and Prostate Cancer Risk and Treatment
- Schaeffer reads TRAVERSE as reassuring: no more prostate cancers were diagnosed on testosterone than on placebo, and PSA still works as a monitoring tool, though Attia notes the trial was small and short enough that a real difference could have been missed.
- The androgen receptor saturation theory holds that prostate tissue saturates at low serum testosterone, roughly 200-250 ng/dL, while muscle needs much higher levels, so raising testosterone should have limited effect on the prostate.
- Aggressive prostate tumors tend to have lower androgen receptor activity and rely on other growth pathways, and the Decipher and GRID tools can measure this from biopsy or surgical tissue.
- Schaeffer would continue TRT in patients diagnosed with low-grade cancer on surveillance, and for higher-grade disease he favors surgery over radiation to avoid androgen deprivation and keep testosterone replacement possible.
- PSA is a very sensitive recurrence biomarker, which lets urologists use early salvage therapy instead of routine adjuvant hormone suppression, unlike breast cancer.
IDEAS WORTH REMEMBERING
5 ideasTRAVERSE offers reassurance but has limits for prostate cancer
Only about 23 cancers were detected in the trial, with no excess on testosterone, but Attia noted the incidence curves diverged slightly and the study may have been too short or small to show a difference.
The prostate may saturate at low testosterone levels
Schaeffer says prostate and hair follicle androgen receptors likely saturate near 200-250 ng/dL, helped by conversion of testosterone to the roughly 10 times more potent DHT, while muscle needs much higher levels to benefit.
Testosterone raises BPH symptoms more than cancer risk
Benign prostate cells have higher androgen receptor density and are more sensitive to supplementation, so studies tend to show worsened urinary symptoms rather than cancer development or progression.
Aggressive tumors often have low androgen receptor output
Schaeffer's lab found that more aggressive tumors rely less on canonical androgen receptor signaling and use other pathways such as PTEN and MYC, which links back to the NEJM observation that lower testosterone and PSA accompanied higher-grade cancer.
Low-grade cancer on surveillance does not require stopping TRT
Schaeffer says there is no evidence that exogenous testosterone accelerates prostate cancer, and he would monitor a man on TRT at 800 the same way as a man naturally at 800.
WORDS WORTH SAVING
5 quotesThere's no evidence that says, uh, exogenous T replacement, uh, causes acceleration or propagation of someone's prostate cancer.
— Ted Schaeffer
if you can treat someone's localized prostate cancer and save them the morbidity from systemic hormonal therapy, that's a huge win for the patient.
— Ted Schaeffer
Those would be like, the way I explain to the patients are, those are weeds in your garden that have just... They're really large above the surface, but have very thin, tiny roots.
— Ted Schaeffer
So instead of just taking this bazooka approach, you can be a sniper.
— Peter Attia
the tumors that develop in a low T environment, they're less dependent on androgens to grow. They often use other growth pathways to be aggressive. And actually, I think they're more, they're more worrisome because you don't exactly know how you're gonna attack it or treat it if it actually progresses.
— Ted Schaeffer
High quality AI-generated summary created from speaker-labeled transcript.
